<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-12-58-a</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-12-8-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Metabolic Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pyridoxine-Dependent Seizures and MRI Changes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>08</month>
<year>1998</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>05</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<issue>8</issue>
<fpage>58</fpage>
<lpage>58</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1998 The Author(s)</copyright-statement>
<copyright-year>1998</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1212/WNL.51.1.74" vol="51" page="74">
<article-title>Longitudinal MRI findings in pyridoxine-dependent seizures</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>Longitudinal brain MRI findings in two patients presenting with neonatal, pyridoxine-dependent seizures and followed for 5 to 9 years are reported from the University of California, Davis, CA.</p>
</abstract>
<kwd-group>
<kwd>Pyridoxine-Dependent Seizures</kwd>
<kwd>Hypotonia</kwd>
<kwd>Neonatal Onset</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Longitudinal brain MRI findings in two patients presenting with neonatal, pyridoxine-dependent seizures and followed for 5 to 9 years are reported from the University of California, Davis, CA. Each patient had three serial MRIs, showing progressive dilation of ventricles and atrophy of cortex and white matter. Patient 1 with AED-resistant seizures was diagnosed at 3.5 months by IV 100 mg pyridoxine administration during EEG monitoring. Seizures characterized by lip smacking, tonic eye deviation, and limb jerking began 2 hours after birth and were initially responsive to phenobarbital. Treatment with 25 mg oral pyridoxine daily controlled seizures, but noncompliance resulted in prolonged seizures and severe developmental disability with hypotonia at 5 year follow-up. Patient 2 developed seizures consisting of eye deviation and facial twitching and responsive to phenobarbital at 4 days after birth. They recurred occasionally up to 8 months of age, when seizures became refractory to anticonvulsants and were found to respond to pyridoxine. During follow-up for 9 years, minor motor seizures, partial and generalized, occurred only during intercurrent illness or noncompliance with pyridoxine, 25 mg daily, treatment. Seizures were preceded by sleepiness and irritability. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. Pyridoxine-dependent seizures of neonatal onset and due to an inborn abnormality of GABA synthesis, if undiagnosed and untreated, can result in progressive cerebral atrophy and severe impairments of psychomotor development. Previous reports have emphasized that the control of seizures alone may not suffice in treating pyridoxine dependency. In order to prevent mental retardation and motor and language delay, it may be necessary to increase the dose of pyridoxine to 10 mg/kg/daily to normalize neurotoxic glutamate levels. Language and cognitive disabilities secondary to pyridoxine-dependency may be partially reversed using optimal pyridoxine dosage. (See <underline>Progress in Pediatric Neurology III</underline>, PNB Publ, 1997;pp93-98).</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gospe</surname>
<given-names>SM</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hecht</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Longitudinal MRI findings in pyridoxine-dependent seizures</article-title>
<source>Neurology</source>
<year>1998</year>
<month>Jul</month>
<volume>51</volume>
<issue>1</issue>
<fpage>74</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.51.1.74</pub-id>
<pub-id pub-id-type="pmid">9674782</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>